August 4, 2020

Volume X, Number 217

August 03, 2020

Subscribe to Latest Legal News and Analysis

Comments Sought by December 19th on the FDA's Proposed Criteria for "First Generic" Applications

This morning, the Food and Drug Administration (FDA) opened a public docket and requested comments on its proposed criteria for expedited review of "first generic" Abbreviated New Drug Applications (ANDAs). The comment period ends on December 19, 2014. If you would like assistance submitting a comment, please contact any of the attorneys listed in this advisory.

This public docket follows up on the Office of Generic Drug's public hearing held on September 17, 2014. Opening this docket is a step in implementing the Generic Drug User Fee Amendments of 2012 (GDUFA), specifically the FDA's commitments to: (1) expedite review of potential first-to-file ANDAs; (2) try to act within 30 months of submission to avoid forfeiture of 180-day exclusivity for failure to timely obtain tentative approval; and (3) expedite review of "first generic" ANDAs for which there are no blocking patents or exclusivities.

The FDA proposes defining a "first generic" application as a received ANDA: (1) that is eligible for 180-day exclusivity, or for which there are no blocking patents or exclusivities; and (2) for which there is no previously approved ANDA for the drug product. Review of these ANDAs would be prioritized by the FDA, although an ANDA could potentially lose its priority treatment due to "changes in the patent or exclusivity landscape," which could include a finding of infringement in Hatch-Waxman patent litigation.

The FDA seeks comments regarding these criteria for "first generics," including whether the FDA should change the review prioritization for an ANDA that no longer meets these criteria at some point during its review. The FDA also seeks comments on mechanisms by which ANDA applicants could timely submit information relevant to an ANDA's ongoing eligibility for expedited treatment as a first generic (e.g., developments in related patent litigation).

The FDA's online notice posted today is available here.

©2020 Katten Muchin Rosenman LLPNational Law Review, Volume IV, Number 323

TRENDING LEGAL ANALYSIS


About this Author

Matthew Holub, Intellectual Property Legal Specialist, Katten Law Firm
Associate

Matthew M. Holub concentrates his practice on resolving intellectual property disputes, including complex patent litigation involving the Hatch-Waxman Act and Abbreviated New Drug Applications. Matt also applies his strong foundation in the pharmaceutical industry to various complex litigation matters, including both antitrust and contractual claims.

Matt is well-versed in all stages of trial practice, and has extensive experience with pleadings, electronic discovery and motion practice. His awareness that clients desire to quickly reach beneficial resolutions has made him an...

312.902.5326
Brian Sodikoff, Patent Litigator, Katten Law Firm, Chicago Office
Partner

Brian Sodikoff advises clients on patent, trademark, copyright and trade secret matters. He devotes a significant part of his practice to complex patent litigation and has worked on all phases of cases involving a diverse array of technologies, including thermoplastic air bag covers, automated truck transmissions, DVD technology and hard disk drives. 

A registered patent attorney, Brian prosecutes and secures patents, partnering with clients to design and implement customized strategies to create strong patent protection that transforms ideas...

312-902-5462